Insider Selling: Keros Therapeutics (NASDAQ:KROS) Insider Sells 3,568 Shares of Stock

Posted by Francis Steltz on Aug 20th, 2026

Keros Therapeutics, Inc. (NASDAQ:KROS – Get Free Report) insider Lorena Raquel Lerner sold 3,568 shares of the stock in a transaction that occurred on Tuesday, August 18th. The stock was sold at an average price of $10.29, for a total transaction of $36,714.72. Following the completion of the sale, the insider owned 27,559 shares of the company’s stock, valued at approximately $283,582.11. The trade was a 11.46% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Keros Therapeutics Stock Down 1.4%

Shares of Keros Therapeutics stock traded down $0.15 on Thursday, hitting $10.95. 203,071 shares of the company traded hands, compared to its average volume of 339,802. Keros Therapeutics, Inc. has a 12-month low of $9.69 and a 12-month high of $22.55. The company has a market cap of $217.14 million, a PE ratio of -2.96 and a beta of 0.99. The company has a 50-day moving average price of $10.67 and a 200 day moving average price of $11.90.

Keros Therapeutics (NASDAQ:KROS – Get Free Report) last announced its quarterly earnings data on Monday, August 3rd. The company reported ($1.45) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.34) by ($0.11). Keros Therapeutics had a negative return on equity of 21.40% and a negative net margin of 256.60%. Equities research analysts anticipate that Keros Therapeutics, Inc. will post -5.16 EPS for the current year.

Hedge Funds Weigh In On Keros Therapeutics

Several hedge funds have recently bought and sold shares of KROS. Caitong International Asset Management Co. Ltd raised its holdings in Keros Therapeutics by 254.6% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 1,624 shares of the company’s stock valued at $33,000 after buying an additional 1,166 shares in the last quarter. Tower Research Capital LLC TRC boosted its stake in shares of Keros Therapeutics by 149.2% during the 2nd quarter. Tower Research Capital LLC TRC now owns 3,153 shares of the company’s stock worth $42,000 after acquiring an additional 1,888 shares in the last quarter. Legal & General Group Plc bought a new stake in shares of Keros Therapeutics during the 2nd quarter worth about $90,000. PDT Partners LLC acquired a new position in shares of Keros Therapeutics during the 2nd quarter valued at about $122,000. Finally, Lazard Asset Management LLC acquired a new position in shares of Keros Therapeutics during the 1st quarter valued at about $129,000. 71.56% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently issued reports on KROS shares. Weiss Ratings reiterated a “sell (d-)” rating on shares of Keros Therapeutics in a report on Wednesday, August 12th. Zacks Research downgraded Keros Therapeutics from a “hold” rating to a “strong sell” rating in a report on Wednesday, July 29th. Wall Street Zen lowered shares of Keros Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Sunday. Wells Fargo & Company reduced their target price on shares of Keros Therapeutics from $20.00 to $18.00 and set an “overweight” rating for the company in a research note on Tuesday, August 4th. Finally, HC Wainwright reiterated a “buy” rating and issued a $20.00 target price on shares of Keros Therapeutics in a research note on Tuesday, August 4th. Four analysts have rated the stock with a Buy rating, three have given a Hold rating and two have given a Sell rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Hold” and an average price target of $20.50.

Check Out Our Latest Stock Analysis on Keros Therapeutics

Keros Therapeutics Company Profile

(Get Free Report)

Keros Therapeutics, Inc (NASDAQ: KROS) is a clinical-stage biopharmaceutical company dedicated to discovering and developing novel therapies for disorders of erythropoiesis and iron regulation. The company’s research centers on modulating the transforming growth factor-beta (TGF-β) superfamily to rebalance hematopoiesis and improve red blood cell production. By targeting key signaling pathways involved in anemia, Keros aims to provide new treatment options for patients with myelodysplastic syndromes, beta-thalassemia and other chronic anemias with significant unmet need.

The company’s lead product candidate, KER-050, is an engineered activin receptor ligand trap designed to restore effective erythropoiesis and reduce transfusion dependence in patients with anemia associated with myelodysplastic syndromes and primary myelofibrosis.